India’s Patent Laws Under Scrutiny, Ramifications Huge for Generics

India’s patent laws are coming under more intense scrutiny, with cases that could add new difficulties for foreign multinational companies. India’s Supreme Court is wrapping up a case between Novartis and the Indian patent office. The case centers on whether the company’s patent for its cancer drug Glivec (imatinib mesylate) is viable in India under the Patents Amendment Act of 2005.
Generic Line